Story

Avita Medical Stock Surges on Record Revenue and Raised Full-Year Guidance

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20262 min read
Avita Medical Stock Surges on Record Revenue and Raised Full-Year Guidance
Text size
Background

Shares of Avita Medical (RCEL) surged more than 20% in pre-market trading after the regenerative medicine company announced record quarterly results and an upgraded financial outlook, signaling strong commercial momentum.

Record Quarter and Upgraded Outlook

Avita Medical reported second-quarter revenue of $21.7 million, an 18% increase year-over-year that beat analyst consensus estimates by approximately 8%. The company also posted a narrower-than-expected adjusted loss per share of $0.25, compared to the consensus forecast of a $0.30 loss.

Buoyed by the strong performance, management raised its full-year 2026 revenue guidance. The company now expects revenue to be in the range of $86 million to $89 million, a significant increase from its prior forecast of $80 million to $85 million. Avita also reaffirmed its goal of achieving cash flow breakeven in the fourth quarter of 2026.

Analyst Upgrade Adds to Momentum

The strong earnings report was followed by an analyst upgrade from BTIG, which raised its rating on Avita Medical stock from Neutral to Buy and set a price target of $7.00. The firm cited the company's improved execution and the record quarterly revenue beat as key reasons for the upgrade.

Sample IUX Markets – In-articleAd

This combination of a top- and bottom-line earnings beat, a material guidance increase, and a timely analyst endorsement created a powerful set of catalysts for the stock. The move was specific to the company, as the broader S&P 500 and NASDAQ indexes showed only modest gains.

Operational Drivers

On an earnings call, CEO Cary Vance noted that reimbursement uncertainty, a headwind in the previous year, has been progressively resolved through work with Medicare Administrative Contractors. The company's key commercial products, including RECELL, demonstrated strong sequential growth during the quarter.

This performance reinforces investor confidence in the company's commercial execution, which had been a point of concern in prior periods. Management anticipates that coding changes expected in 2027 will further reduce friction for healthcare providers using its products.

Read next

More on Stocks
Back to latest news

LATEST